Genentech announced this week that it would be investing $450 million into a new biologics manufacturing facility at its Oceanside, California campus.
According to the California-based biotech, the new site will feature transformational digital technologies to produce medicines more efficiently. The facility's modular design will enable simultaneous production of multiple medicines as well as the ability to quickly pivot from producing one medicine to another.
Genentech is also pledging to integrate a sustainable design into its construction and production, which will become fully operational in early 2025.
To support operations, the drugmaker plans to add approximately 150 local, full-time jobs, in addition to workers engaged during construction.
The facility’s location was chosen due to its proximity to Genentech’s Clinical Supply Center in South San Francisco.
